SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Gloved hand holding a vial of mpox vaccine
Vaccines
Bavarian Nordic’s Mpox Shot Shows Antibody Responses Wane After 6 to 12 Months: Study
While a JAMA study found a decline in mpox antibody responses after vaccination, a University of Oxford expert cautioned that there is still not enough evidence to determine if this decline also leads to waning protections.
October 4, 2024
 · 
2 min read
 · 
Tristan Manalac
Gilead's headquarters in Silicon Valley
Infectious disease
Gilead Partners With Generics Developers to Provide HIV Drug to Low-Income Countries
Gilead Sciences is granting licenses to six companies to produce lenacapavir for pre-exposure prophylaxis, as well as for treating human immunodeficiency virus in heavily pre-treated adults with multidrug-resistant infections.
October 3, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Sign of U.S. Department of Health & Huma
IRA
CMS Releases Updated Medicare Drug Price Negotiation Guidance, Offers More Flexible Timeline
The adjusted guidelines will provide drugmakers with more opportunities to engage with the Centers for Medicare and Medicaid Services regarding the initial maximum fair price offers, according to the agency.
October 3, 2024
 · 
1 min read
 · 
Tristan Manalac
U.S. and Chinese flags in concrete, broken in the middle
BIOSECURE Act
WuXi Mulls Sale of Some US, European Operations: FT
The Financial Times reported Thursday that WuXi AppTec is looking to sell its cell and gene therapy manufacturing unit, with facilities in Philadelphia, while WuXi Biologics wants to offload some of its production sites in Europe.
October 3, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: An Eli Lilly Research Laboratories sign/
Supply chain
Lilly’s Tirzepatide No Longer on FDA Drug Shortage List
BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes and weight loss drugs are gaining market share as manufacturing continues to expand, while noting the drugmaker could start to benefit heading into third quarter earnings.
October 3, 2024
 · 
2 min read
 · 
Tristan Manalac
Phoenix, Arizona/
Business
Meeting on the Mesa to Highlight Cell and Gene Therapy Opportunities, Challenges
Stephen Majors from the Alliance for Regenerative Medicine, which hosts the conference, spoke with BioSpace about what the more than 2,000 attendees can expect to learn next week in Phoenix about the pressing issues confronting the industry.
October 3, 2024
 · 
7 min read
 · 
Greg Slabodkin
Giant robot flicking tiny man. Ai technologies and unemployment problem concept. Vector illustration.
Layoffs
More Layoffs From ImmunityBio, Bringing California’s Fall Cuts to 31
ImmunityBio will lay off 15 employees in California, mostly in El Segundo, effective Nov. 25. The company is also letting go 16 employees later this month.
October 2, 2024
 · 
1 min read
 · 
Angela Gabriel
Held back metaphor as a large anchor holding or oppressing an air balloon and restricting movement as a suppression business metaphor from aspiring to succeed with 3D illustration elements.
Cell Therapy
As 2seventy Nears Breakeven, CEO Chip Baird Explains How the Team Survived
To say that 2seventy bio’s short two years of existence have been dramatic is an understatement. CEO Chip Baird told BioSpace transparency and a committed staff have kept the biotech going through thick and thin.
October 2, 2024
 · 
8 min read
 · 
Annalee Armstrong
Group Of Employees Being Fired By Their Company.
Layoffs
Bayer, J&J and Pfizer to Lay Off Nearly 500 Combined Employees
Big Pharma companies Bayer and Johnson & Johnson are downsizing their New Jersey workforces while Pfizer cuts jobs in Ireland. Many of the layoffs are effective by the end of the year.
October 2, 2024
 · 
3 min read
 · 
Angela Gabriel
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS